Mebeverine Zentiva

Mebeverine Hydrochloride, the active ingredient in Mebeverine Zentiva, is an antispasmodic (smooth muscle relaxant) presented as an oral tablet for oral use. It is employed to relieve abdominal cramping and discomfort associated with functional gastrointestinal disorders, particularly irritable bowel syndrome. GNH USA supplies Mebeverine Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mebeverine Zentiva is a gastrointestinal antispasmodic that acts on smooth‑muscle tone in the digestive tract. It is indicated for: - Irritable bowel syndrome: reduces abdominal pain, bloating and irregular bowel movements. - Functional gastrointestinal disorders: eases spasm‑related discomfort and improves bowel habit. - Spastic colon: alleviates colonic muscle spasms and associated cramping.

Adverse reactions may occur with any medication. Most are mild and reversible.

Common Side Effects: - Nausea: occasional mild stomach upset. - Dry mouth: reduced salivation. - Headache: transient mild headache. - Dizziness: light‑headed sensation. - Abdominal discomfort: mild cramps. - Constipation: occasional reduced bowel movements.

Serious or Rare Side Effects: - Allergic reactions: rash, itching, swelling, or angioedema. - Severe hypotension: marked drop in blood pressure. - Cardiac arrhythmia: irregular heart rhythm in susceptible individuals.

Before prescribing Mebeverine Zentiva, clinicians should consider several safety aspects. - Pregnancy: safety not established; use only if clearly needed. - Breastfeeding: unknown excretion; weigh benefits against potential risks. - Elderly: monitor for anticholinergic effects such as confusion or urinary retention. - Hepatic or renal impairment: dose adjustment may be required. - Drug interactions: review concomitant medications for additive anticholinergic load. - Store at below 25°C: keep in the original pack, protect from moisture.

Mebeverine may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase mebeverine plasma concentrations. - Other anticholinergic agents: additive anticholinergic burden can worsen side effects. - Monoamine oxidase inhibitors: potential for increased cardiovascular effects.

Moderate Interactions (Monitor Closely): - Antidiarrheal agents (e.g., loperamide): may reduce therapeutic benefit. - Tricyclic antidepressants: may enhance anticholinergic adverse events. - Antihistamines: can increase dry‑mouth and dizziness risk.